Changing Natural History of HER2–Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies

Patients with breast cancer brain metastases historically have a poor prognosis. In this single-institution cohort study of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases, we found no improvement in survival after brain recurrence over time desp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical breast cancer 2018-02, Vol.18 (1), p.29-37
Hauptverfasser:	Mounsey, Louisa A., Deal, Allison M., Keith, Kevin C., Benbow, Julia M., Shachar, Shlomit S., Zagar, Timothy, Dees, E. Claire, Carey, Lisa A., Ewend, Matthew G., Anders, Carey K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Brain metastases Brain Neoplasms - drug therapy Brain Neoplasms - mortality Brain Neoplasms - secondary Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Disease-Free Survival Female Follow-Up Studies Humans Kaplan-Meier Estimate Lapatinib Middle Aged Molecular Targeted Therapy - methods Mortality - trends Outcome Prognosis Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - metabolism Retrospective Studies TDM-1 Trastuzumab Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!